LB-102 not checked

LB Pharmaceuticals Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Schizophrenia (2 trials), Bipolar I Disorder
Main trialPhase 3
“This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.”In the company’s words, NCT07363577 on ClinicalTrials.gov

Other drugs for Schizophrenia

All 40 drugs for Schizophrenia

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2027 Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
Phase 3Recruiting Dec 2028 52-week Open Label Safety-Tolerability Study
Phase 2Recruiting Feb 2028 Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
Phase 2Completed 4 Dec 2024 Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Phase 1Completed 17 Sep 2021 Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LB-102

Following is part of Solo: you see every change to LB-102 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in